Search Results 511-520 of 21300 for Inhibition

  1. Team approach for optimal tumor care - Mayo Clinic

    ... inhibitors for potential treatment of H3K27M ... STAT3 inhibitor reduces H3K27M tumor growth Enlarge image.

  2. Upadacitinib (oral route) - Side effects & dosage - Mayo Clinic

    Upadacitinib is a Janus kinase (JAK) inhibitor that works on the immune system. This medicine is available only with your doctor's prescription. This ...

  3. Endocrinology, Diabetes and Metabolism Training Program student roster - Mayo Clinic Research

    Mentor. Paul Haluska, M.D.. Research focus. Palliation of ovarian cancer ascites via PAPP-A inhibition and repositioning antimalarial drug quinacrine to enhance ...

  4. Epithelial-Mesenchymal Transition in Breast Cancer - Tumor Microenvironment Laboratory - Mayo Clinic Research

    Recognition of the relationship between matrix metalloproteinases and malignancy led to clinical trials of broad-spectrum MMP inhibitors as cancer therapeutics, ...

  5. Mayo Clinic Q and A: 5 advances in cancer treatment

    The first checkpoint inhibitor was approved by the Food and Drug Administration in 2011 to treat melanoma. Since then, 15 more immune checkpoint inhibitors ...

  6. Researchers reduce inflammation in human cells, A major cause of frailty - Mayo Clinic News Network

    Senescent cells are cells that contribute to frailty and diseases associated with aging. Also, these same JAK inhibitors reduced inflammatory mediators in mice.

  7. Bladder control: Medications for urinary problems - Mayo Clinic

    Duloxetine (Cymbalta, Drizalma Sprinkle) is a serotonin and norepinephrine reuptake inhibitor that is approved to treat depression and anxiety. It can help ...

  8. Naltrexone and bupropion (oral route) - Side effects & dosage - Mayo Clinic

    ... inhibitor. Wait 2 weeks after stopping naltrexone and bupropion combination before you start taking a MAO inhibitor. If you take them together or do not ...

  9. New hope for ovarian cancer Video Audio Vivien Williams

    PARP inhibitors block the protein from functioning, so cancer cells die. Andrea Wahner Hendrickson, M.D.. "Ovarian cancer is a tumor that, thankfully, does ...

  10. Understanding the role of proteolytic activity in mediating irritable bowel syndrome symptoms and disruption of intestinal barrier function - Mayo Clinic

    Serine protease inhibitors, but not cysteine protease inhibitors ... And pharmacological or siRNA inhibition of protease-activated receptor-2 diminished these ...